SIADH and hyponatraemia: Foreword

CKJ: Clinical Kidney Journal

Volumn 2, Issue SUPPL.3, 2009, Pages

  O'Donoghue, Donal ^a   Trehan, Anu ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

hyponatraemia; SIADH; vasopressin; vasopressin receptor antagonists

Indexed keywords

EID: 77953633766     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp152     Document Type: Review

References (23)

1. Adrogue HJ, Madias NE, Hyponatremia. New Eng J Med 2000; 342: 1581-1589
2. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119(Suppl): S30-S35
3. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations. Am J Med 2007; 120(11A): S1-S21
4. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006; 119(7A): S79-S82
5. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. New Eng J Med 2007; 356: 2064-2072
6. Movig KL, Leufkens HG, Lenderink AW et al. Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol 2003; 56: 530-535
7. Hoorn EJ, Lindemans J, Zieste R. Development of severe hyponatremia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006; 21: 70-76
8. Decaux G. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Semin Nephrol 2009; 29: 239-256
9. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106: 399-403
10. Palewsky PM, Rendulic D, Diven WF. Maltose-induced hyponatremia. Ann Intern Med 1993; 118: 5526-5528
11. Rhymer JC, Bell TJ, Perry KC et al. Hyponatremia following transurethral resection of the prostate. Br J Urol 1985; 57: 450-452
12. van der Lubbe N, Thompson CJ, Zietse R et al. The clinical challenge of SIADH-three cases. NDT Plus 2009; 2(Suppl 3): iii20-iii24
13. Zietse R, van der Lubbe N, Hoorn EJ. Current and future treatment options in SIADH. NDT Plus 2009; 2(Suppl 3): iii12-iii19
14. Upadhyay A, Jaber BL, Madias NE et al. Epidemiology of hyponatremia. Semin Nephrol 2009; 3: 227-238
15. Renneboog B, Musch W, Vandemergel X et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med 2006; 119: 71.e1-71.e8.
16. Arieff AI, Ayus JC. Hip fractures associated with symptomatic hyponatremia (abstract). J Am Soc Nephrol 2001; 12: 133
17. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996: 156: 1814-1820
18. Terzian C, Frye EB, Piotrowski ZH. Admission hyponatremia in elderly: factors influencing prognosis. J GenMed 1994; 9: 89-91
19. Anderson RJ, Chung HM, Kluge R et al. Hyponatremia:a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102: 164-168
20. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the US. Cost Effectiveness Resource Allocation 2006; 4: 10
21. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results form a double-blind, randomized trial. Circulation 2003; 107: 2690-2696
22. Gheorghiade M, Gattis WA, O'Connoir CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalised with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971
23. Schrier RW, Gross P, GheorghiadeMet al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist for hyponatremia. N Eng J Med 2006; 355: 2099-2112